Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s share price fell 7.3% during trading on Friday . The stock traded as low as $11.94 and last traded at $12.83. 101,442 shares were traded during trading, a decline of 94% from the average session volume of 1,768,739 shares. The stock had previously closed at $11.96.

Several research firms have commented on FOLD. ValuEngine upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Tuesday, July 10th. Chardan Capital downgraded shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $18.00 to $15.00 in a research note on Friday, August 17th. Finally, BidaskClub downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.43.

The company has a market cap of $2.44 billion, a price-to-earnings ratio of -4.11 and a beta of 1.26. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.33). Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. The business had revenue of $21.31 million for the quarter, compared to the consensus estimate of $18.92 million. analysts anticipate that Amicus Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

In related news, CFO William D. Baird III sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $15.63, for a total value of $156,300.00. Following the transaction, the chief financial officer now owns 117,622 shares of the company’s stock, valued at approximately $1,838,431.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Kurt J. Andrews sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $15.63, for a total transaction of $78,150.00. Following the completion of the transaction, the senior vice president now directly owns 40,469 shares in the company, valued at approximately $632,530.47. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Amicus Therapeutics by 6.1% in the 2nd quarter. BlackRock Inc. now owns 16,017,301 shares of the biopharmaceutical company’s stock worth $250,190,000 after buying an additional 927,049 shares during the period. Redmile Group LLC increased its position in Amicus Therapeutics by 7.1% during the 1st quarter. Redmile Group LLC now owns 10,738,658 shares of the biopharmaceutical company’s stock valued at $161,509,000 after purchasing an additional 712,888 shares during the period. Palo Alto Investors LP increased its position in Amicus Therapeutics by 2.4% during the 1st quarter. Palo Alto Investors LP now owns 6,147,829 shares of the biopharmaceutical company’s stock valued at $92,463,000 after purchasing an additional 141,807 shares during the period. Morgan Stanley increased its position in Amicus Therapeutics by 519.6% during the 2nd quarter. Morgan Stanley now owns 4,968,627 shares of the biopharmaceutical company’s stock valued at $77,610,000 after purchasing an additional 4,166,756 shares during the period. Finally, Franklin Resources Inc. increased its position in Amicus Therapeutics by 1.3% during the 1st quarter. Franklin Resources Inc. now owns 3,767,389 shares of the biopharmaceutical company’s stock valued at $56,661,000 after purchasing an additional 48,490 shares during the period.

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

See Also: Technical Analysis

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.